Scarica l'app Stockscreener
7.25
6.30%
0.43
Pre-mercato:
7.24
-0.010
-0.14%
Vanda Pharmaceuticals Inc Borsa (VNDA) Ultime notizie
Vanda Pharmaceuticals (NASDAQ:VNDA) Share Price Passes Above 200-Day Moving AverageHere's Why - MarketBeat
Vanda Pharmaceuticals stock faces institutional dominance amid biotech sector volatility and retail - AD HOC NEWS
Gastroparesis Pipeline 2026: FDA Updates, Therapy Innovations, and Clinical Trial Landscape Analysis by DelveInsight | CinDome Pharma, Inc., Evoke Pharma, Vanda Pharmaceuticals, Ironwood Pharma - Barchart
Gastroparesis Pipeline 2026: FDA Updates, Therapy - openPR.com
Vanda Pharmaceuticals Inc.(NasdaqGM:VNDA) added to S&P Biotechnology Select Industry Index - marketscreener.com
Vanda Pharmaceuticals Faces New Market Challenges Amid Share Sale and Regulatory Roadblocks - timothysykes.com
If You Invested $1,000 in Vanda Pharma (VNDA) - Stock Titan
Insider Sell: Can Vanda Pharmaceuticals Inc ride the EV wave2026 PostEarnings & Intraday High Probability Setup Alerts - baoquankhu1.vn
CEO’s Significant Stock Sale Raises Concerns for Vanda Pharmaceuticals - timothysykes.com
Vanda Pharmaceuticals Faces Shareholder Movements and Regulatory Setbacks - StocksToTrade
Vanda Pharmaceuticals Inc. (VNDA) latest stock news and headlines - Yahoo Finance Singapore
Vanda stock draws heavy buzz ahead of FDA verdict on Bysanti for bipolar, schizophrenia - MSN
Vanda Pharmaceuticals Raises Concerns Over FDA's New Guidance on Drug Development - Intellectia AI
VNDA Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
What's going on with Vanda Pharma stock Tuesday? - MSN
Vanda Pharmaceuticals Faces Setbacks as CEO Mihael Polymeropoulos Sells Shares - StocksToTrade
Vanda Pharmaceuticals urges FDA to accelerate move away from animal testing - Traders Union
Vanda Pharmaceuticals Calls for Stronger FDA Action to Accelerate Shift from Animal Testing to Human-Relevant Methods - Bitget
Vanda Pharmaceuticals Calls for Stronger FDA Action to Accelerate Shift from Animal Testing to Human-Relevant Methods – Company AnnouncementFT.com - Financial Times
Hedge Fund Moves: Is Vanda Pharmaceuticals Inc a strong candidate for buy and holdSwing Trade & Low Risk Entry Point Guides - baoquankhu1.vn
Vanda Pharmaceuticals (NASDAQ:VNDA) Shares Gap UpTime to Buy? - MarketBeat
Growth Report: Will Vanda Pharmaceuticals Inc outperform tech stocks2026 Decliners & AI Forecast for Swing Trade Picks - baoquankhu1.vn
Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) Receives Average Recommendation of "Moderate Buy" from Analysts - MarketBeat
Vanda Pharmaceuticals Stock (ISIN: US92178N1054) Faces Heightened Scrutiny Amid Pipeline Setbacks an - AD HOC NEWS
Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) Sees Significant Growth in Short Interest - MarketBeat
CEO Moves: Why is Vanda Pharmaceuticals Inc stock going up2026 Market Overview & Precise Swing Trade Alerts - baoquankhu1.vn
Why did Vanda Pharmaceuticals stock slide 7% pre-market today? - MSN
Why Vanda Pharmaceuticals (VNDA) Is Up 17.4% After Rare FDA Hearing Granted On HETLIOZ Jet Lag - Yahoo Finance
DC Circ. Spends Hours Debating 'Same' Generic Label Reqs - Law360
Vanda Pharmaceuticals Hits New 52-Week High of $9.94, Surges 59.87% - Markets Mojo
Truist initiates Vanda Pharmaceuticals stock at buy on drug pipeline - Investing.com Nigeria
Vanda Pharmaceuticals (VNDA) Is Up 13.3% After Rare FDA Hearing Granted on HETLIOZ Jet Lag Bid - simplywall.st
Vanda Advances NEREUS Launch With Direct-to-Consumer Strategy - The Globe and Mail
Vanda Pharmaceuticals at The Citizens Life Sciences Conference: Strategic Growth Insights - Investing.com Canada
VNDA: BYSANTI and Nereus launches drive growth, with key pipeline milestones expected by year-end - TradingView
Vanda Pharmaceuticals (VNDA) price target increased by 15.96% to 13.90 - MSN
Vanda Pharmaceuticals (NASDAQ: VNDA) CEO outlines DTC channel for FDA-approved motion drug - Stock Titan
Vanda Pharmaceuticals (NASDAQ:VNDA) Sets New 52-Week HighWhat's Next? - MarketBeat
Vanda Pharmaceuticals (NASDAQ:VNDA) Trading Up 8.1%Should You Buy? - MarketBeat
Vanda surges as FDA approves Bysanti for bipolar disorder, schizophrenia - MSN
VNDA Stock Soars 40% Overnight After Bysanti Approval: What’s The Next Catalyst And How Much Upside Remains? - Stocktwits
Truist Financial Begins Coverage on Vanda Pharmaceuticals (NASDAQ:VNDA) - MarketBeat
Truist initiates Vanda Pharmaceuticals stock at buy on drug pipeline By Investing.com - Investing.com Australia
Truist Securities Initiates Coverage on Vanda Pharmaceuticals (V - GuruFocus
Truist Initiates Vanda Pharmaceuticals at Buy With $18 Price Target - marketscreener.com
Vanda Pharmaceuticals (NASDAQ:VNDA) CMO Joakim Wijkstrom Sells 30,800 Shares - MarketBeat
Kevin Patrick Moran Sells 42,442 Shares of Vanda Pharmaceuticals (NASDAQ:VNDA) Stock - MarketBeat
Insider Selling: Vanda Pharmaceuticals (NASDAQ:VNDA) SVP Sells 42,434 Shares of Stock - MarketBeat
Gunther Birznieks Sells 42,431 Shares of Vanda Pharmaceuticals (NASDAQ:VNDA) Stock - MarketBeat
Insider Selling: Vanda Pharmaceuticals (NASDAQ:VNDA) CEO Sells 156,235 Shares of Stock - MarketBeat
Executive at Vanda (NASDAQ: VNDA) sells shares to cover RSU taxes - Stock Titan
[Form 4] Vanda Pharmaceuticals Inc. Insider Trading Activity - Stock Titan
1.82%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):